642411-11-8

Basic information

• Product Name: Diethyl 1-benzylazetidine...
• Synonyms: Diethyl 1-benzylazetidine...;Diethyl 1-benzylazetidine-3,3-dicarboxylate;3,3-Azetidinedicarboxylic acid, 1-(phenylMethyl)-, diethyl ester;3,3-diethyl 1-benzylazetidine-3,3-dicarboxylate;diethyl 1-(phenylmethyl)-3,3-azetidinedicarboxylate
• CAS NO: 642411-11-8
• Molecular Formula: C₁₆H₂₁NO₄
• Molecular Weight: 203
• Mol File: 642411-11-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Diethyl 1-benzylazetidine...(CAS DataBase Reference)
• NIST Chemistry Reference: Diethyl 1-benzylazetidine...(642411-11-8)
• EPA Substance Registry System: Diethyl 1-benzylazetidine...(642411-11-8)

Safety Data

• Hazardous Substances Data: 642411-11-8(Hazardous Substances Data)

Usage

General Description

Diethyl 1-benzylazetidine-2,2-dicarboxylate is a chemical compound used in the synthesis of pharmaceuticals and organic compounds. It is a bicyclic compound containing a benzene ring and an azetidine ring, and its diethyl ester form makes it easier to handle and use in various reactions. Diethyl 1-benzylazetidine... has potential applications in drug development and organic synthesis, as its structure and properties make it suitable for creating new molecules with pharmaceutical or industrial significance. Its unique chemical properties and reactivity make it an important compound in the field of organic chemistry and drug discovery.

Upstream product

• 100-46-9 benzylamine 
• 642411-10-7 diethyl 2,2-bis((((trifluoromethyl)sulfonyl)oxy)methyl)malonate 
• 20605-01-0 diethyl bis(hydroxymethyl)malonate 
• 105-53-3 diethyl malonate 

Downstream Products

• 103491-30-1 ethyl 1-benzylazetidine-3-carboxylate 
• 1011479-75-6 1-(tert-butyl) 3,3-diethyl azetidine-1,3,3-tricarboxylate 
• 1078166-50-3 ethyl 1-benzyl-3-(hydroxymethyl)azetidine-3-carboxylate 
• 26096-30-0 N-benzyl-3,3-bis-(hydroxymethyl)-azetidine 
• 1016233-34-3 1-[(7-benzyloxymethyl-4-tert-butoxy-9-deazapurin-9-yl)methyl]azetidine-3,3-dimethanol 
• 1016232-92-0 azetidine-3,3-dimethanol hydrochloride 
• 1016233-08-1 3,3-bis(hydroxymethyl)azetidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF

A compound of Formula (I) or or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating hearing loss or balance disorder: Formula (I) wherein R1 and Y are as defined herein.

Targeting Alzheimer's disease by investigating previously unexplored chemical space surrounding the cholinesterase inhibitor donepezil

A series of twenty seven acetylcholinesterase inhibitors, as potential agents for the treatment of Alzheimer's disease, were designed and synthesised based upon previously unexplored chemical space surrounding the molecular skeleton of the drug donepezil, which is currently used for the management of mild to severe Alzheimer's disease. Two series of analogues were prepared, the first looking at the replacement of the piperidine ring in donepezil with different sized saturated N-containing ring systems and the second looking at the introduction of different linkers between the indanone and piperidine rings in donepezil. The most active analogue 5,6-dimethoxy-1-oxo-2,3-dihydro-1H-inden-2-yl 1-benzylpiperidine-4-carboxylate (67) afforded an in vitro IC50value of 0.03 ± 0.07 μM against acetylcholinesterase with no cytotoxicity observed (IC50of >100 μM, SH-SY5Y cell line). In comparison donepezil had an IC50of 0.05 ± 0.06 μM and an observed cytotoxicity IC50of 15.54 ± 1.12 μM. Molecular modelling showed a strong correlation between activity and in silico binding in the active site of acetylcholinesterase.

FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS

The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.